Bone Graft
-
Biologics
5,000 patients treated with OssDsign Catalyst® in the U.S.
Uppsala, May 30, 2024. Today, OssDsign AB (publ.) announces that the company continues its successful penetration of the U.S. orthobiologics…
Read More » -
Spine
1,000 patients treated with OssDsign® Catalyst in the U.S.
Uppsala, May 9, 2023 – OssDsign AB (publ.) today announces that 1,000 patients have been treated in the U.S. with…
Read More » -
Biologics
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
Company plans to begin 30-patient trial later this year April 11, 2023 BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a…
Read More » -
Biologics
Ventris Medical Receives 510(k) Clearance for Amplify® Standalone Bone Graft Putty and Bone Graft Extender
NEWPORT BEACH, Calif., Sept. 14, 2022 /PRNewswire/ — Ventris Medical, a privately held orthobiologics and tissue regeneration company, today announced that the…
Read More »